MedTrace Logo

LOW-PV Continuation

NCT06752941 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2025-12-26

No results posted yet for this study

Summary

This multicenter longitudinal observational study focuses on Italian patients with Polycythemia Vera (PV) who were enrolled in the Low-PV RCT and continued receiving Ropeginterferon alfa-2b until the study's conclusion on March 31, 2023. It includes patients who were responders to Ropeginterferon alfa-2b after two years in the phase II randomized trial "LOW-PV." Data will be collected retrospectively every 6 months from March 31, 2023 to November 30, 2024 and prospectively from December 1, 2024 to March 31, 2026.

Conditions

Sponsors & Collaborators

  • FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

    lead OTHER

Principal Investigators

  • TIZIANO BARBUI, MD · FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-30
Primary Completion
2026-03-30
Completion
2026-03-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06752941 on ClinicalTrials.gov